Fig. 6

LINC00623 is a potential therapeutic target for PDAC. a Graphical diagram of intratumoral injection of in vivo optimized LINC00623 inhibitor in PDX-bearing mice. b Representative images of xenograft tumors derived from PDX1 or PDX2 in each mouse group. Mice bearing xenograft tumors were treated with antisense oligonucleotide control (ASO-Ctrl) or an in vivo optimized LINC00623 inhibitor (ASO-LINC00623). Xenograft tumor growth was monitored by measuring the tumor volume every six days (c) and weighing the tumors (d). Tumor volume and weight are expressed as the mean ± SD of five mice (*P < 0.05, **P < 0.01; independent Student’s t test). e Representative images of H&E staining, IHC staining and FISH of xenograft tumors. Scale bar = 50 μm. f Schematic diagram of the effect of the LINC00623/NAT10 axis on the tumorigenicity and progression of PDAC